XML 21 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Marketable Securities
6 Months Ended
Jun. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities
6.
Marketable securities

As of June 30, 2024, the Company had $713,863 of available-for-sale securities (December 31, 2023 – trading securities of $13,867 and available-for-sale-securities of $768,364). Amortized cost, unrealized gain (loss) recognized in accumulated other comprehensive loss and fair value of available-for-sale securities consisted of the following:

 

 

 

June 30, 2024

 

 

December 31, 2023

 

 

 

Amortized
Cost

 

 

Unrealized
Gain (Loss)

 

 

Fair
Value

 

 

Amortized
Cost

 

 

Unrealized
Gain (Loss)

 

 

Fair
Value

 

Contractual maturity of 0 to 1 years:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Guaranteed investment certificates

 

$

15,360

 

 

$

(245

)

 

$

15,115

 

 

$

7,549

 

 

$

135

 

 

$

7,684

 

U.S. treasuries

 

 

133,833

 

 

 

(122

)

 

 

133,711

 

 

 

192,193

 

 

 

(249

)

 

 

191,944

 

U.S. government securities

 

 

53,580

 

 

 

(150

)

 

 

53,430

 

 

 

98,092

 

 

 

(180

)

 

 

97,912

 

Commercial paper

 

 

156,519

 

 

 

(72

)

 

 

156,447

 

 

 

119,041

 

 

 

67

 

 

 

119,108

 

Corporate debt securities

 

 

226,337

 

 

 

(239

)

 

 

226,098

 

 

 

58,824

 

 

 

100

 

 

 

58,924

 

Contractual maturity of 1 to 3 years:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasuries

 

 

47,992

 

 

 

(272

)

 

 

47,720

 

 

 

53,294

 

 

 

243

 

 

 

53,537

 

Corporate debt securities

 

 

81,464

 

 

 

(122

)

 

 

81,342

 

 

 

238,458

 

 

 

797

 

 

 

239,255

 

Total

 

$

715,085

 

 

$

(1,222

)

 

$

713,863

 

 

$

767,451

 

 

$

913

 

 

$

768,364

 

Allowance for credit losses or impairment on these marketable securities have not been recognized as these securities are high credit quality, investment grade securities that the Company does not intend to sell and will not be required to sell prior to their anticipated recovery, and the decline in fair value is primarily due to changes in interest rates.